Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Envveno Medical Corp (NQ: NVNO )

5.750 +0.250 (+4.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 34,674
Open 5.510
Bid (Size) 5.540 (1)
Ask (Size) 5.760 (34)
Prev. Close 5.500
Today's Range 5.510 - 5.760
52wk Range 3.400 - 6.970
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
Via ACCESSWIRE
Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting
Via ACCESSWIRE

Performance

YTD
+12.75%
+12.75%
1 Month
+10.58%
+10.58%
3 Month
+9.94%
+9.94%
6 Month
+33.10%
+33.10%
1 Year
+15.00%
+15.00%

More News

Read More
New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024
Via ACCESSWIRE
NVNO Stock Earnings: enVVeno Medical Beats EPS for Q1 2024
Via InvestorPlace
enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
Via ACCESSWIRE
enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
Via ACCESSWIRE
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
Via ACCESSWIRE
Recap: enVVeno Medical Q4 Earnings
Via Benzinga
enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium
Via ACCESSWIRE
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
Via ACCESSWIRE
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
Via ACCESSWIRE
enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
Via ACCESSWIRE
enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium
Via ACCESSWIRE
enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
enVVeno Medical to Participate at the Virtual Investor Ask the CEO Conference
Via ACCESSWIRE
enVVeno Medical Achieves Full Enrollment for VenoValve U.S. Pivotal Trial
Via ACCESSWIRE
enVVeno Medical Announces New Expedited Development Plan for the enVVe(R) Transcatheter Based Replacement Venous Valve
Via ACCESSWIRE
enVVeno Medical Announces Private Placement of $28 Million
Via ACCESSWIRE
enVVeno Medical Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
enVVeno Medical to Host Virtual KOL Event on July 18, 2023
Via ACCESSWIRE
enVVeno Medical Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study and Announces Upcoming Investor and KOL Events
Via ACCESSWIRE
enVVeno Medical Reports First Quarter 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
enVVeno Medical Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.